Wegovy Pills: The Oral GLP-1 Now Approved in the UK

For anyone who has looked into GLP-1 treatments but felt put off by the idea of weekly injections, there is genuinely significant news. The MHRA approved the Wegovy tablet on 12th June 2026, making it the first oral GLP-1 receptor agonist licensed specifically for weight management in the UK.

This is not just a minor product extension. It potentially opens up effective treatment to a large group of people who have either avoided injections or struggled with them long-term. Here is a clear, practical look at what the pill is, how it works, who it suits, and what to expect.

What is the Wegovy pill?#

The Wegovy tablet contains semaglutide, the same active ingredient as the Wegovy injection. It is manufactured by Novo Nordisk and taken once daily, rather than once weekly like the injection. Both forms target the same biological pathways and produce broadly similar weight loss results in clinical trials.

Semaglutide has been used in oral form for type 2 diabetes under the brand name Rybelsus for several years. What makes the Wegovy pill different is that it uses higher doses and is specifically licensed for weight management in adults with obesity or overweight with weight-related health conditions. Rybelsus is not interchangeable with the Wegovy pill for this purpose.

The reason an oral semaglutide pill is technically challenging relates to the nature of the molecule itself. Semaglutide is a peptide, and peptides are usually broken down by stomach acid before they can be absorbed. The Wegovy tablet gets around this using SNAC technology (salcaprozate sodium), an absorption enhancer that temporarily raises the local pH around the tablet and helps the semaglutide pass through the stomach lining intact.

How it compares to the injection#

The practical differences between the tablet and the injection are worth understanding clearly before making any decision.

Frequency: The tablet is taken every day. The injection is taken once a week. Some people find a daily routine easier to maintain; others prefer the once-weekly approach.

Administration: A tablet is straightforward and familiar. No needles, no sharps disposal, no refrigeration requirements for travel, and considerably more discreet in workplace or social situations.

Dosing schedule: The titration schedules differ. The tablet starts at a lower dose and moves through several stages over three months to reach the full maintenance dose of 25mg daily. The injection reaches its maintenance dose of 2.4mg weekly over a similar period but via a different set of dose steps.

Absorption requirements: This is the biggest practical difference. The tablet must be taken first thing in the morning on a completely empty stomach, swallowed whole with no more than 120ml of plain water. You then need to wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medications. If you miss that window regularly, the medication will not be absorbed properly and its effectiveness will be reduced.

Efficacy: Clinical trial data suggest broadly comparable weight loss outcomes. The OASIS 4 trial, a 71-week randomised placebo-controlled study, found that participants taking oral semaglutide lost approximately 15% of their body weight on average at the full 25mg dose, compared to around 3% in the placebo group. The STEP 1 trial for the 2.4mg weekly injection found roughly 16.9% mean weight loss over a similar period. These are not identical but are in the same range.

If you are already on the injection and curious about switching, this should always be done with clinical guidance. The doses are not directly equivalent and the changeover needs to be planned carefully to avoid gaps or accidental overlap.

Totiva's weight loss service covers both injectable and oral semaglutide options, with pharmacist-led consultations to help you work out which approach fits your situation.

The dosing schedule#

Understanding the titration plan helps set realistic expectations and makes it easier to build the right daily habits from the start.

The standard dose progression is:

• Days 1-30: 1.5mg once daily
• Days 31-60: 4mg once daily
• Days 61-90: 9mg once daily
• Day 91 onwards: 25mg once daily (maintenance)

Each step up brings a gradual increase in the medication's effect on appetite and gastric emptying. Side effects, particularly nausea, tend to be most noticeable during dose increases and typically ease once the body has adjusted.

The 30-minute fasting window is not just a recommendation. It directly affects how much of the medication you actually absorb. Food, coffee, tea, juice, or most other medications taken within that window will significantly reduce absorption. If you find this difficult to manage consistently, it is worth discussing with your prescriber. Shift workers, parents of young children, and people with early morning commitments often need to think through how this fits their routine before starting. One practical approach is to keep the tablet, a small glass of water, and your phone timer on your bedside table so you can take it before you even get up.

Who is eligible?#

The eligibility criteria for the Wegovy pill mirror those for the injection. You may be suitable if you have:

• A BMI of 30 or above, or
• A BMI of 27 or above alongside a weight-related health condition such as type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnoea, or cardiovascular disease

A prescriber will review your full medical history, current medications, and individual circumstances before confirming whether it is appropriate for you.

The tablet is not suitable if you have:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• A known hypersensitivity to semaglutide or any of the tablet's ingredients
• Pancreatitis (current or history of severe episodes)
• Severe gastrointestinal disease including gastroparesis

Pregnancy and breastfeeding are also contraindications. If there is any chance you could become pregnant, effective contraception is important, and the interaction with oral contraceptives is worth raising specifically with your prescriber (see drug interactions below).

Side effects#

Because the Wegovy pill and the injection share the same active ingredient, their side effect profiles are very similar. The majority are gastrointestinal and are most noticeable when doses are increasing.

Common side effects include:

• Nausea (most common, especially in the early weeks)
• Vomiting
• Diarrhoea or constipation
• Indigestion and bloating
• Stomach discomfort
• Fatigue, particularly in the first few weeks
• Headaches

These effects usually improve as your body adjusts. Taking the tablet correctly, eating smaller meals, avoiding very fatty or spicy food, and staying hydrated can all help manage them.

Less common but more serious risks include pancreatitis, gallbladder problems (including gallstones), and, based on animal studies, a potential association with thyroid C-cell tumours. The thyroid risk has not been confirmed in humans but is the reason for the contraindication in people with a relevant personal or family history.

Drug interactions#

Because semaglutide slows gastric emptying, it can affect how other oral medications are absorbed. This is particularly relevant for:

• Combined oral contraceptives: Absorption may be reduced, particularly during dose escalation. Your prescriber may recommend using barrier contraception as a backup for the first few months.
• Levothyroxine: Timing matters here. People taking levothyroxine should discuss with their prescriber how to manage the interaction, as both medications are typically taken in the morning on an empty stomach.
• Statins and antihypertensives: Generally considered lower risk but worth disclosing to your prescriber so timing can be optimised.
• SSRIs and other psychiatric medications: No specific contraindication, but inform your prescriber as part of a full medication review.

This is not an exhaustive list. Always give your prescriber a complete picture of everything you take, including supplements and over-the-counter medications.

NHS access and private availability#

The MHRA approval on 12th June 2026 clears the regulatory hurdle, but that does not automatically mean NHS availability. The NHS pathway for a newly approved medicine typically requires a NICE technology appraisal before NHS commissioning decisions are made. NICE appraisals can take 12 to 18 months or more from the point of licensing.

At the time of writing, it is not confirmed whether NICE will appraise the Wegovy pill as a separate assessment from the injection, or whether an existing appraisal will be updated. Given that NICE has already appraised injectable semaglutide for weight management (TA875), there is reasonable expectation that oral semaglutide will be considered in due course, but no confirmed timeline exists yet.

Scotland follows a separate pathway through the Scottish Medicines Consortium (SMC), which independently assesses medicines for use within NHS Scotland. The SMC has its own timeline and criteria, so availability in Scotland may differ from England and Wales even after a NICE decision.

Privately, the Wegovy pill is available through registered UK online pharmacies and weight management services from July 2026. When accessing any treatment privately, it is important to use a GPhC-registered pharmacy or prescribing service. The MHRA has specifically warned against buying GLP-1 medications from unregulated online sources, where counterfeit or incorrectly dosed products are a genuine risk.

Totiva is a GPhC-registered UK pharmacy offering pharmacist-led consultations for weight management. If you want to find out whether you are eligible for the Wegovy tablet or want to discuss your options properly, you can start a consultation here.

What about Wegovy pills for men?#

Most of the initial coverage around the Wegovy pill has been framed around women who want to avoid injections. That is a valid and significant population, but it is worth being clear that the medication is approved for adults with obesity generally, regardless of sex.

Men with a BMI of 30 or above, or 27 or above with weight-related conditions, are equally eligible. The efficacy and safety data from the OASIS 4 trial included both male and female participants. If injection aversion, travel requirements, workplace discretion, or simply preference for a tablet over an injection is a factor for you, the eligibility criteria are the same.

Will weight come back if you stop?#

This is one of the most important questions to understand clearly before starting any GLP-1 treatment. The honest answer is: for most people, yes, at least some weight is likely to return after stopping.

Data from injectable semaglutide trials show that participants who stopped treatment regained a significant portion of the weight they had lost within a year. This reflects the underlying biology. Semaglutide works by actively modifying appetite and gut signalling. When you stop taking it, those signals return to baseline.

This does not mean treatment is not worthwhile. For many people, the metabolic improvements, reduction in cardiovascular risk, and quality of life gains during treatment are clinically meaningful. But it does mean that obesity is best understood as a long-term condition that may require ongoing management rather than a short course of treatment.

If you are considering stopping or pausing, speak to your prescriber first rather than stopping abruptly.

A practical note on the morning routine#

One thing that does not always get enough attention in clinical discussions is how much the absorption requirements can affect real daily life. The 30-minute window works well for people with a consistent morning routine, but it needs planning for others.

Practical strategies that work for different situations:

• Shift workers: Take the tablet at whatever time you wake, regardless of the clock. The key is consistency and empty stomach, not a specific hour.
• People taking levothyroxine: Discuss with your prescriber the safest way to space the two medications. Many people end up taking one on waking and one after the 30-minute window.
• Commuters: Set a phone alarm before your alarm, take the tablet, and use the 30 minutes for getting ready.
• Parents with early morning demands: Preparing the evening before (glass of water and tablet on the bedside table) removes one decision from a chaotic morning.

Consistency matters much more than perfection. An occasional slip will not undermine treatment, but a persistent pattern of poor absorption will.